Akari Therapeutics PLC (NASDAQ:AKTX)‘s stock had its “buy” rating reiterated by equities researchers at Canaccord Genuity in a research note issued on Friday. They currently have a $15.00 price target on the biopharmaceutical company’s stock. Canaccord Genuity’s price target would suggest a potential upside of 83.37% from the company’s current price.

The analysts wrote, “Date and time of first dissemination: September 21, 2017, 23:12 ET Date and time of production: September 21, 2017, 20:41 ET Target Price / Valuation Methodology: Impax Laboratories – IPXL Our $19 price target is derived from a blend of DCF (7.7% WACC, +1% terminal growth) and a 9.2x forward EV/EBITDA on our 2018 estimates. IPXL shares currently trade around 8x our 2018 EV/EBITDA compared to a group average of around 9.2x. We think a group average EV/EBITDA valuation is warranted because of potential P&L leverage growing profitability faster than revenue which warrants a premium, a premium warranted for the company’s well-respected leadership offset by a discount to the group for relatively low expected top-line growth and a low-duration FTF/FTM based generics pipeline.””

Other equities research analysts also recently issued research reports about the company. William Blair raised Akari Therapeutics PLC from a “market perform” rating to an “outperform” rating in a report on Friday. Chardan Capital reissued a “neutral” rating on shares of Akari Therapeutics PLC in a report on Sunday, September 17th. Zacks Investment Research raised Akari Therapeutics PLC from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. Finally, ValuEngine raised Akari Therapeutics PLC from a “strong sell” rating to a “sell” rating in a report on Monday, September 11th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $8.00.

Akari Therapeutics PLC (NASDAQ AKTX) traded down 6.41% during midday trading on Friday, hitting $8.18. The stock had a trading volume of 3,632,740 shares. The company’s market capitalization is $96.33 million. The company’s 50-day moving average price is $4.17 and its 200 day moving average price is $7.23. Akari Therapeutics PLC has a 52 week low of $3.18 and a 52 week high of $22.20.

WARNING: This report was originally reported by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.dailypolitical.com/2017/09/22/akari-therapeutics-plc-aktx-earns-buy-rating-from-canaccord-genuity.html.

An institutional investor recently bought a new position in Akari Therapeutics PLC stock. Hikari Power Ltd acquired a new position in Akari Therapeutics PLC (NASDAQ:AKTX) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 60,012 shares of the biopharmaceutical company’s stock, valued at approximately $277,000. Hikari Power Ltd owned approximately 0.51% of Akari Therapeutics PLC at the end of the most recent quarter. 26.85% of the stock is currently owned by institutional investors.

About Akari Therapeutics PLC

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.

Receive News & Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.